MX2024002259A - Acido nucleico producido biologicamente para la produccion de vacunas. - Google Patents
Acido nucleico producido biologicamente para la produccion de vacunas.Info
- Publication number
- MX2024002259A MX2024002259A MX2024002259A MX2024002259A MX2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A MX 2024002259 A MX2024002259 A MX 2024002259A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- acid sequence
- cov
- sars
- biologically produced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
- C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21195643 | 2021-09-09 | ||
| EP22179777 | 2022-06-19 | ||
| PCT/EP2022/075140 WO2023036947A1 (en) | 2021-09-09 | 2022-09-09 | Biologically produced nucleic acid for vaccine production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002259A true MX2024002259A (es) | 2024-03-06 |
Family
ID=83558295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002259A MX2024002259A (es) | 2021-09-09 | 2022-09-09 | Acido nucleico producido biologicamente para la produccion de vacunas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250188127A1 (https=) |
| EP (1) | EP4398935A1 (https=) |
| JP (1) | JP2024533378A (https=) |
| KR (1) | KR20240055051A (https=) |
| AU (1) | AU2022341555A1 (https=) |
| CA (1) | CA3224963A1 (https=) |
| IL (1) | IL310010A (https=) |
| MX (1) | MX2024002259A (https=) |
| WO (1) | WO2023036947A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022543046A (ja) * | 2019-07-30 | 2022-10-07 | バーンダリ・インコーポレイテッド | ウイルス様粒子ワクチン |
-
2022
- 2022-09-09 EP EP22783448.8A patent/EP4398935A1/en active Pending
- 2022-09-09 US US18/690,452 patent/US20250188127A1/en active Pending
- 2022-09-09 JP JP2024515395A patent/JP2024533378A/ja active Pending
- 2022-09-09 AU AU2022341555A patent/AU2022341555A1/en active Pending
- 2022-09-09 KR KR1020247010899A patent/KR20240055051A/ko active Pending
- 2022-09-09 IL IL310010A patent/IL310010A/en unknown
- 2022-09-09 MX MX2024002259A patent/MX2024002259A/es unknown
- 2022-09-09 WO PCT/EP2022/075140 patent/WO2023036947A1/en not_active Ceased
- 2022-09-09 CA CA3224963A patent/CA3224963A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024533378A (ja) | 2024-09-12 |
| KR20240055051A (ko) | 2024-04-26 |
| AU2022341555A1 (en) | 2024-01-18 |
| WO2023036947A1 (en) | 2023-03-16 |
| IL310010A (en) | 2024-03-01 |
| EP4398935A1 (en) | 2024-07-17 |
| AU2022341555A9 (en) | 2024-01-25 |
| CA3224963A1 (en) | 2023-03-16 |
| US20250188127A1 (en) | 2025-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022011685A2 (es) | Vacunas de arn contra el coronavirus | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| CL2021000028A1 (es) | Anticuerpo multiespecifico (divisional de solicitud 937-2020). | |
| MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| BR112018008078A2 (pt) | vacina de vírus influenza de amplo espectro | |
| DOP2017000175A (es) | Dinucleótidos cíclicos útiles en el tratamiento del cáncer | |
| CO2018012513A2 (es) | Anticuerpos | |
| BR112022014830A2 (pt) | Formulações de vacina para coronavírus | |
| AR113257A1 (es) | Virus chikungunya inmunogénico | |
| CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
| CL2021002168A1 (es) | Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407). | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
| ZA202100384B (en) | Influenza virus hemagglutinin mutants | |
| MX2023007228A (es) | Constructo de arn. | |
| AR056133A1 (es) | Virus de influenza canina y composiciones relacionadas y metodos de uso | |
| BR112018012355A2 (pt) | composição dermocosmética, processo de produção da composição tópica, método para fortalecimento de unhas frágeis e uso da composição | |
| MX2024002259A (es) | Acido nucleico producido biologicamente para la produccion de vacunas. | |
| MX2024004252A (es) | Vacunas antigripales multivalentes. | |
| MX2022010928A (es) | Ácido nucleico de cadena larga, completamente sintético para la producción de vacunas para protección contra coronavirus. | |
| AR051923A1 (es) | Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus | |
| BR112022009545A2 (pt) | Método para produzir vírus influenza recombinantes | |
| PE20251751A1 (es) | Variantes de lfa3 y composiciones y usos de las mismas |